Study protocol of a prospective single-arm multicenter clinical study to assess the safety and performance of the aXess hemodialysis graft: The pivotal study

Autor: An S De Vriese, Annick D’Haeninck, Artur Mendes, Augusto Ministro, Dainis Krievins, David Kingsmore, Gaspar Mestres, Gonzalo Villanueva, Hugo Rodrigues, Jakub Turek, Maciej Zieliński, Jan De Letter, Andreia Coelho, Luís Alvarenga Loureiro, Matteo Tozzi, Mirko Menegolo, Palma Fariñas Alija, Panagiotis G Theodoridis, Paul Gibbs, Reze Ebrahimi, Sigi Nauwelaers, Stavros K Kakkos, Vladimir Matoussevitch, Frans Moll, Mauro Gargiulo
Rok vydání: 2023
Předmět:
Zdroj: The Journal of Vascular Access. :112972982311749
ISSN: 1724-6032
1129-7298
DOI: 10.1177/11297298231174932
Popis: Background: Arteriovenous grafts (AVGs) are used for patients deemed unsuitable for the creation of an autogenous arteriovenous fistula (AVF) or unable to await maturation of the AVF before starting hemodialysis. However, AVGs are prone to infection and thrombosis resulting in low long-term patency rates. The novel aXess Hemodialysis Graft consists of porous polymeric biomaterial allowing the infiltration by cells and the growth of neotissue, while the graft itself is gradually absorbed, ultimately resulting in a fully functional natural blood vessel. The Pivotal Study will examine the long-term effectiveness and safety of the aXess Hemodialysis Graft. Methods: The Pivotal Study is a prospective, single-arm, multicenter study that will be conducted in 110 subjects with end-stage renal disease who are not deemed suitable for the creation of an autogenous vascular access. The primary efficacy endpoint will be the primary patency rate at 6 months. The primary safety endpoint will be the freedom from device-related serious adverse events at 6 months. The secondary endpoints will include the procedural success rate, time to first cannulation, patency rates, the rate of access-related interventions to maintain patency, the freedom from device-related serious adverse events and the rate of access site infections. Patients will be followed for 60 months. An exploratory Health Economic and Outcomes Research sub-study will determine potential additional benefits of the aXess graft to patients, health care institutions, and reimbursement programs. Discussion: The Pivotal study will examine the long-term performance and safety of the aXess Hemodialysis Graft and compare the outcome measures with historical data obtained with other graft types and autogenous AVFs. Potential advantages may include superior long-term patency rates and lower infection rates versus currently available AVGs and a shorter time to first cannulation compared to an autologous AVF. As such, the aXess Hemodialysis Graft may fulfill an unmet clinical need in the field of hemodialysis access.
Databáze: OpenAIRE
Externí odkaz: